Effects of oral SCH 527123, a CXCR2 antagonist, on acquired immunity in healthy adults

S. Khalilieh, C. Kasserra, M. Tsai, M. Seiberling, M. Kraan (Kenilworth, NJ, United States Of America; Allschwil, Switzerland)

Source: Annual Congress 2007 - New insights into the treatment of COPD
Session: New insights into the treatment of COPD
Session type: Thematic Poster Session
Number: 3600
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Khalilieh, C. Kasserra, M. Tsai, M. Seiberling, M. Kraan (Kenilworth, NJ, United States Of America; Allschwil, Switzerland). Effects of oral SCH 527123, a CXCR2 antagonist, on acquired immunity in healthy adults. Eur Respir J 2007; 30: Suppl. 51, 3600

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
SCH 527123, a CXCR2 antagonist, inhibits ozone-induced airway neutrophilia in healthy subjects
Source: Annual Congress 2007 - New drugs for COPD
Year: 2007


Rising multiple-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy smokers
Source: Annual Congress 2007 - New insights into the treatment of COPD
Year: 2007


Preclinical safety profile of oral SCH 527123, a novel antagonist of CXCR2
Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II
Year: 2007


Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CSCR2, in healthy volunteers
Source: Annual Congress 2007 - New insights into the treatment of COPD
Year: 2007


Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 219s
Year: 2004

In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist
Source: Eur Respir J 2007; 30: Suppl. 51, 25s
Year: 2007

Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations
Source: Eur Respir J 2004; 24: Suppl. 48, 109s
Year: 2004

In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407
Source: Eur Respir J 2007; 30: Suppl. 51, 26s
Year: 2007

The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan
Source: Annual Congress 2010 - Airway smooth muscle cells
Year: 2010

GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Year: 2020


Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019




The cannabinoid receptor agonist, WIN 55,212-2, inhibits antigen-induced plasma extravasation in guinea pig airways
Source: Annual Congress 2010 - Models of airways disease
Year: 2010


IDL-2965: A Selective, highly-potent, oral Integrin antagonist for IPF
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019

Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012

Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist
Source: Eur Respir J 2001; 18: Suppl. 33, 264s
Year: 2001

Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012


CS-003, a novel triple neurokinin receptor antagonist, inhibits symptoms of respiratory diseases models in guinea pigs
Source: Eur Respir J 2006; 28: Suppl. 50, 664s
Year: 2006

A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011

Distinct effects of the endothelin receptor antagonists PD 142893 (ET-A/B), BQ 788 (ET-B) and N-Ac-Trp-ET 1 Frg. 16-21 (ET-A) on oxidative stress-induced pulmonary hypertension in isolated rabbit lungs
Source: Eur Respir J 2001; 18: Suppl. 33, 198s
Year: 2001

Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD
Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease
Year: 2010